[Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon (author's transl)].
The antiandrogen-containing preparation SH B 209 AB was tested in comparison with an ovulation inhibitor with no antiandrogenic effect (Neogynon) in a randomized, double blind study conducted to determine the effects of both on androgenization symptoms. 88 patients took part in the study. In the majority of cases the duration of the treatment period was more than 6 months. It was shown that the therapy with the combination preparation containing cyproterone acetate was distinctly more successful in cases of acne and seborrhoea: not only acne in its various locations but also all forms of seborrhoea were more favourably influenced by the trial preparation. This difference was statistically significant (p less than 0.05). It was not possible to establish a significant difference between the two preparations in the case of hirsutism in its various locations from the limited number of cases observed. There were also no differences detected in hepatic tolerance. During treatment with both preparations all values measured were within the normal range.
D000152:Acne Vulgaris / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003534:Cyproterone / Q000627:therapeutic use*; D012628:Dermatitis, Seborrheic / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004361:Drug Tolerance; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000627:therapeutic use
D009644:Norgestrel; D004997:Ethinyl Estradiol; D003534:Cyproterone
Zur Beeinflussung von Androgenisierungserscheinungen. Doppelblindstudie eines cyproteronacetathaltigen Präparats (SH B 209 AB) gegen Neogynom.